In summary, we did not find significantly worse cognitive function in breast cancer survivors with an APOE ε4 allele over time, nor any particular vulnerability in the presence of chemotherapy exposure or endocrine therapy across timepoints. The gene discussed is APOE; the disease is breast cancer.